Hewlett J S, Chen T, Balcerzak S P, Gutterman J U, Costanzi J J, Amare M
Arch Intern Med. 1985 Jun;145(6):1006-12.
In this Southwest Oncology Group (SWOG) study, 216 adults with acute leukemia were treated with ten-day chemotherapy consisting of vincristine sulfate (Oncovin), cytarabine (ara-C) (100 mg per square meter of body area per day by 24-hour infusion), and prednisone (ten-day OAP). The results were compared with those of a previous SWOG study in which cytarabine (200 mg per square meter of body area per day) was given for five days (five-day OAP). Patients entering complete remission (CR) were given three consolidation courses of five-day OAP and randomized to maintenance chemotherapy alone (32 patients) or combined with BCG vaccine (24 patients). For 160 previously untreated patients with acute myelogenous leukemia, there was no difference in remission rates (53% vs 43%) or median survival times (48 vs 47 weeks) between ten-day and five-day OAP. The difference in duration of CR (74 vs 54 weeks, respectively) between the two maintenance arms was not statistically significant. However, 14% of evaluable patients with acute myelogenous leukemia and 26% of those achieving CR were alive and in remission more than five years.
在西南肿瘤协作组（SWOG）的这项研究中，216名成年急性白血病患者接受了为期十天的化疗，化疗方案包括硫酸长春新碱（安可平）、阿糖胞苷（ara-C）（每天每平方米体表面积100毫克，持续24小时静脉输注）和泼尼松（为期十天的OAP方案）。研究结果与SWOG之前的一项研究进行了比较，在之前的研究中阿糖胞苷的剂量为每天每平方米体表面积200毫克，疗程为五天（为期五天的OAP方案）。进入完全缓解（CR）的患者接受了三个疗程的为期五天的OAP巩固化疗，并被随机分为单纯接受维持化疗组（32例患者）或联合卡介苗疫苗组（24例患者）。对于160例既往未接受过治疗的急性髓性白血病患者，为期十天和五天的OAP方案在缓解率（53%对43%）或中位生存时间（48周对47周）方面没有差异。两个维持治疗组之间的CR持续时间差异（分别为74周和54周）无统计学意义。然而，14%可评估的急性髓性白血病患者和26%达到CR的患者存活且缓解超过五年。
